Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
SAN DIEGO, Aug. 13, 2024 /PRNewswire/ — Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx Biosciences” or the “Company”), a biopharmaceutical company with two programs in ongoing clinical trials and a strong emerging pipeline, today reported financial results for the second quarter of 2024 and provided an update on recent corporate highlights. Separation from the Former Parent … Read more
